Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 8:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 15,938 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arm 2 Clear all
Active, not recruiting Phase 2 Interventional Results available

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

NCT01416831
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Radiation therapy and high-dose IL-2, High-dose IL-2
Other · Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 26, 2026, 8:47 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tocilizumab on Patients With COVID-19

NCT04356937
View directory record Official record
Conditions
SARS-CoV 2
Interventions
Tocilizumab, Placebos
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 26, 2026, 8:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ERr 731® Formulation Evaluation

NCT05959057
View directory record Official record
Conditions
Menopause
Interventions
ERr 731 - Micro-coated, ERr 731 - Enteric coated
Dietary Supplement
Lead sponsor
Metagenics, Inc.
Industry
Eligibility
35 Years to 64 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Gig Harbor, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 26, 2026, 8:47 AM EDT
Completed Not applicable Interventional

Music Therapy to Address Patients' Journeys With Chronic Illness, Outcomes, and Readmission - MAJOR CHORD RCT

NCT06546319
View directory record Official record
Conditions
Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
Music Therapy
Behavioral
Lead sponsor
Samuel Rodgers-Melnick
Other
Eligibility
30 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 26, 2026, 8:47 AM EDT
Completed Phase 3 Interventional

Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy

NCT03050827
View directory record Official record
Conditions
Diabetic; Neuropathic, Polyneuropathy (Manifestation)
Interventions
3% oxybutynin, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 26, 2026, 8:47 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

NCT03206203
View directory record Official record
Conditions
Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative, Invasive Breast Cancer
Interventions
Atezolizumab, Carboplatin, Laboratory Biomarker, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 26, 2026, 8:47 AM EDT
Completed Phase 1 Interventional

Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers

NCT05220046
View directory record Official record
Conditions
Pancreas Cancer, Biliary Tract Cancer, Psychological Distress, Gastrointestinal Cancer
Interventions
Psilocybin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 26, 2026, 8:47 AM EDT
Terminated Phase 1 Interventional

Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

NCT01348503
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Lenalidomide, Sorafenib
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 26, 2026, 8:47 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

NCT00620282
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, glimepiride
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 26, 2026, 8:47 AM EDT
Terminated Not applicable Interventional Results available

Effectiveness of Precision Spinal Cord Stimulation With Artisan Paddle Electrode

NCT00386724
View directory record Official record
Conditions
Back Pain, Chronic Pain, Pain in Leg, Unspecified
Interventions
Precision Spinal Cord Stimulation System, Artisan Surgical Lead
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Charleston, South Carolina • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 26, 2026, 8:47 AM EDT
Recruiting Not applicable Interventional

Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study

NCT07581080
View directory record Official record
Conditions
Cancer, Immunotherapy, Fatigue Related to Cancer Treatment, Pain, Stress
Interventions
Usui Reiki Intervention
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 26, 2026, 8:47 AM EDT
Completed Not applicable Interventional

Time Limited Eating in Adolescents With Type 2 Diabetes (KT2D)

NCT04536480
View directory record Official record
Conditions
Pediatric Obesity, Type 2 Diabetes, Time Restricted Eating
Interventions
Time Limited Eating, Components Common to All Study Arms., Control, Continuous Glucose Monitor
Behavioral · Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
12 Years to 21 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 26, 2026, 8:47 AM EDT
Recruiting Phase 2 Interventional

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

NCT06997588
View directory record Official record
Conditions
PIK3CA-related Overgrowth Spectrum (PROS)
Interventions
Alpelisib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 100 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Cincinnati, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 26, 2026, 8:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nighttime Macronutrient Choice and Combined Resistance and High-intensity Interval Training

NCT01830946
View directory record Official record
Conditions
Obesity
Interventions
Whey Protein, Combined Resistance and High-Intensity Interval training, Casein Protein
Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 26, 2026, 8:47 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

NCT03985423
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytoses
Interventions
Emapalumab-Lzsg
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 26, 2026, 8:47 AM EDT
Terminated Phase 2 Interventional Results available

Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

NCT02162979
View directory record Official record
Conditions
Parkinson's Disease
Interventions
sildenafil, Placebo
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 26, 2026, 8:47 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism

NCT07649161
View directory record Official record
Conditions
Healthy Adult
Interventions
Niagen®
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 26, 2026, 8:47 AM EDT
Recruiting Not applicable Interventional

Electrical Stimulation Exercise for Individuals With Lower Limb Paralysis

NCT07768761
View directory record Official record
Conditions
Spinal Cord Injury/Disorder, Stroke, Multiple Sclerosis, Traumatic Brain Injury
Interventions
Exercise with Electrical Stimulation
Other
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 26, 2026, 8:47 AM EDT
Completed Not applicable Interventional Results available

Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)

NCT04283994
View directory record Official record
Conditions
Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Lung Diseases, Interstitial, Peripheral Vascular Disease, Diabetes With End Organ Injury
Interventions
Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 26, 2026, 8:47 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Effect of a Probiotic Strain on Aspirin-induced GI Damage

NCT03910322
View directory record Official record
Conditions
Reduction of Small Intestinal Ulceration Risk
Interventions
Bif195, Placebo
Dietary Supplement
Lead sponsor
Chr Hansen
Industry
Eligibility
40 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 26, 2026, 8:47 AM EDT
Terminated Phase 2 Interventional Results available

A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

NCT00457951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Orange, California • Marietta, Georgia • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 26, 2026, 8:47 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated

NCT00025337
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 26, 2026, 8:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Use of Publicly Reported Pediatric Quality Data

NCT01784575
View directory record Official record
Conditions
Pregnancy
Interventions
Patient Navigator Intervention
Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 26, 2026, 8:47 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

NCT05574101
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma of the Skin, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma
Interventions
Cemiplimab, Radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Aurora, Colorado • Tampa, Florida • Basking Ridge, New Jersey + 10 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 26, 2026, 8:47 AM EDT